Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients

2018 ◽  
Vol 104 (4) ◽  
pp. 742-748 ◽  
Author(s):  
Liang Li ◽  
Lian Ma ◽  
Sarah J. Schrieber ◽  
Nam Atiqur Rahman ◽  
Albert Deisseroth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Quantitative Relationship ◽  
Severe Neutropenia ◽  
Breast Cancer Patients

scholarly journals Association of ATP-binding cassette sub-family B member 1 gene C3435T polymorphism with neutropenia in breast cancer patients treated with chemotherapy

2016 ◽  
Vol 25 (3) ◽  
pp. 156-62 ◽  
Author(s):  
Siti Syarifah ◽  
Kamal B. Siregar ◽  
Yahwardiah Siregar
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Common Adverse Event ◽  
Wilcoxon Test ◽  
Atp Binding ◽  
Breast Cancer Patients ◽  
C3435t Polymorphism ◽  
Atp Binding Cassette

Background: Neutropenia is the most common adverse event of breast cancer chemotherapy which can be life threatening due to opportunistic infection, neutropenic episodes may lead to delay or reduction of drug doses which may compromise treatment outcomes. In this study, we investigated the association of ATP-binding cassette sub-family B member 1 (ABCB1) gene C3435T polymorphism with the grading of neutropenia in breast cancer patients who treated with doxorubicin-taxan.Methods: 72 Indonesian female breast cancer patients from Haji Adam Malik Hospital who had been diagnosed and treated with doxorubicin-taxane regimen were selected for this cohort study. DNA was extracted from peripheral leucocytes and ABCB1 C3435T polymorphism was analyzed with PCR-RFLP. Patient data were collected from patient’s medical record for 3 cycles of chemotherapy. Association between ABCB1 C3435T polymorphism with neutropenia was assessed using Kruskal-Wallis test. Decline of absolute neutrophil count was assessed using Wilcoxon test. Genotype deviation and allele frequencies were also determined by Hardy-Weinberg Equilibrium.Results: The frequencies of ABCB1 C3435T genotype for wildtype (CC), heterozygous (CT) and homozygous mutant (TT) was 22 (30.6%), 38 (52.8%) and 12 (16.7%) respectively. No association were found between ABCB1 C3435T polymorphism and the grading of neutropenia (p>0.05). There was a difference on the average of absolute neutrophil count after the first chemotherapy and after the third chemotherapy (p<0.05). There was no significant deviation of allele and genotype frequency from Hardy-Weinberg Equilibrium.Conclusion: ABCB1 C3435T polymorphism had no association with the grading of neutropenia in breast cancer patients treated with doxorubicin-taxane regimen, however there was a trend of absolute neutrophil count declining during the 3 cycles of chemotherapy.

Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 671-671
Author(s):  
K. T. Vance ◽  
J. Carpenter
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Bone Pain ◽  
Common Side Effect ◽  
Breast Cancer Patients ◽  
Dose Dense

671 Background: Pegfilgrastim is indicated to decrease the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. In licensing studies, patients received a single dose of pegfilgrastim on day 2 of each chemotherapy cycle, which added an extra visit for day 2 administration. We administered pegfilgrastim to a series of early breast cancer patients on the same day of chemotherapy. We reviewed charts retrospectively to assess both efficacy and safety. Methods: Data on blood counts, toxicity and chemotherapy dosing was collected from July 1, 2003 to May 6, 2005 for all patients with early breast cancer who received sequential or combination doxorubicin, cyclophosphamide and paclitaxel on a 14 day schedule. Herceptin was given with paclitaxel and/or cyclophosphamide in 2 patients. Results: 64 patients with a median age of 50 years (range 22–67 years) were treated. 14 patients had stage I disease, 39 stage II and 11 stage III disease. Forty-one patients were treated postoperatively and 23 preoperatively. 211 cycles of doxorubicin were administered. After administration of doxorubicin, pegfilgrastim 6 mg s.c. was given on the same day. The lowest absolute neutrophil count on day 14 after doxorubicin was 1693/mm3 with no episodes of febrile neutropenia. The highest absolute neutrophil count was 23,671/mm3. The only dose reductions were five doxorubicin doses for grade 1–2 mucositis. Grade 1–2 nausea and vomiting was the most common toxicity seen after doxorubicin. Grade 1 bone pain was the most common side effect seen after pegfilgrastim occurring in 13/64 patients. There was no grade 3 or 4 toxicity of any kind. Conclusion: Pegfilgrastim administered on the same day as doxorubicin on a 14 day schedule was both safe and effective. Side effects were mild and included bone pain most likely attributable to pegfilgrastim. Neither granulocytopenia nor febrile neutropenia were seen and no treatments were delayed or postponed. Pegfilgrastim given on the same day as chemotherapy was effective in maintaining adequate granulocyte counts to allow treatment 14 days later and to avoid infection from granulocytopenia. Toxicity from pegfilgrastim was mild and tolerable. [Table: see text]

scholarly journals ANALISIS ABSOLUTE NEUTROPHIL COUNT DI PASIEN KANKER PAYUDARA DENGAN KEMOTERAPI (Analysis of Absolute Neutrophil Count in Breast Cancer Patients with Chemotherapy)

2018 ◽  
Vol 21 (3) ◽  
pp. 215
Author(s):  
Arifa Moidady ◽  
Tenri Esa ◽  
Uleng Bahrun
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Relative Number ◽  
Absolute Number ◽  
Age Group ◽  
Breast Cancer Patients ◽  
The Absolute

The Absolute Neutrophil Count (ANC) is the absolute number of neutrophil derived from the multiplication of the relative number ofleukocytes to the total neutrophil count. Neutrophils can be disturbed due to myelosupressive effects of chemotherapy. Fever is a commonsymptom in neutropenia patients due to chemotherapy. This fever is an emergency requiring rapid handling of Oncology and needsadministration of appropriate antibiotics. Therefore, the data on the occurence of neutropenia and its related fever in patients whomaccept chemotherapy after breast cancer it is important to be noted. This study is carried on to know the Absolute Neutrophil Count(ANC) in breast cancer patients with chemotherapy by analyzing them. The study was performed retrospectively by taking medical recorddata from January up to December 2012 in Dr. Wahidin Sudirohusodo Hospital Makassar. The absolute Neutrophil Count pre and afterchemotherapy analysis was done to determine neutropenia, as well as the febrile neutropenia and the correlation between ANC withpatients age and stage of breast cancer. A total of 55 samples with the majority of patients (85.45%) were in the age group of 41–60years old. The ANC after chemotherapy occurred in 50 patients were decreased (90.91%). There are five (5) patients (9.09%) with feverand two (2) persons (patients) (3.63%) suffered febrile neutropenia. The correlation analysis between decreased ANC with patient ageand stage of breast cancer are p=0.054 and 0.070 respectively. Based on this study it can be concluded, that decreased ANC occurredin most patients after accepting chemotherapy but only few patients suffered febrile neutropenia. There was no significant correlationbetween the decreased ANC with patient age and stage of breast cancer.

Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy

2009 ◽  
Vol 18 (2) ◽  
pp. 184-190
Author(s):  
M.A.O. MENDONÇA ◽  
A.H.M. PEREIRA ◽  
S.R. SILVA ◽  
M.C. MARDEGAN ◽  
E.F.C. MURTA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Neutrophil Count ◽  
Breast Cancer Patients

Efficacy and safety of balugrastim in chemotherapy-induced neutropenia: Integrated analysis of two randomized phase III studies.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17572-e17572
Author(s):  
Oleg Gladkov ◽  
Constantin D. Volovat ◽  
Steven Barash ◽  
Anton Buchner ◽  
Noa Avisar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Medical Condition ◽  
Phase Iii ◽  
Severe Neutropenia ◽  
Integrated Analysis ◽  
Efficacy And Safety ◽  
Breast Cancer Patients ◽  
Myelosuppressive Chemotherapy ◽  
Phase Iii Studies

e17572 Background: Balugrastim is a recombinant fusion protein composed of human serum albumin and human granulocyte colony-stimulating factor, which allows for once-per-chemotherapy cycle administration. We present a combined analysis of two double-blind, randomized Phase III studies comparing efficacy and safety of balugrastim vs pegfilgrastim in breast cancer patients receiving myelosuppressive chemotherapy (CTx). Methods: All patients were treated with doxorubicin 60 mg/m2 followed by docetaxel 75 mg/m2 administered by i.v. infusion on Day 1 of a 21-day cycle for up to 4 cycles. For each cycle, patients received a single s.c. injection of balugrastim approximately 24 hours after administration of CTx. The primary endpoint for both studies was duration of severe neutropenia (DSN) in Cycle 1. Safety of balugrastim was assessed by evaluating the type, frequency, and severity of adverse events (AEs); changes in laboratory parameters and vital signs, and immunogenicity over time. Analyses were performed in the per-protocol population. Results: A total of 469 patients were randomized to receive balugrastim 40 mg (N=235) or pegfilgrastim 6 mg (N=234). Mean DSN in Cycle 1 was 1.1±1.11 days in patients receiving balugrastim (n=236) and 1.0±1.14 days in patients receiving pegfilgrastim (n=234). Non-inferiority was demonstrated by statistical analysis for balugrastim vs pegfilgrastim for reduction in DSN across studies. Patients treated with balugrastim had a significantly shorter time to ANC recovery in Cycle 1 vs pegfilgrastim (2.0 vs 2.3 days; P=0.015). No other significant differences were seen between treatment groups in either study for any other secondary endpoints in Cycles 1–4. The safety profile was similar for both drugs, with the incidence of AEs consistent with the underlying medical condition and administration of myelosuppressive CTx. Conclusions: In both Phase III studies, non-inferiority was clearly demonstrated for balugrastim 40 mg vs pegfilgrastim 6 mg. Balugrastim is a safe and effective alternative to long-acting pegfilgrastim for reducing DSN in breast cancer patients receiving myelosuppressive chemotherapy. Clinical trial information: 2010-019001-42.

scholarly journals Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib

The Breast ◽  
2021 ◽  
Author(s):  
Natansh D. Modi ◽  
Ahmad Y. Abuhelwa ◽  
Sarah Badaoui ◽  
Emily Shaw ◽  
Kiran Shankaran ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Severe Neutropenia ◽  
Breast Cancer Patients

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

2004 ◽  
Vol 22 (8) ◽  
pp. 1382-1388 ◽  
Author(s):  
Federico Innocenti ◽  
Samir D. Undevia ◽  
Lalitha Iyer ◽  
Pei Xian Chen ◽  
Soma Das ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Total Bilirubin ◽  
Severe Neutropenia ◽  
Pharmacokinetic Data ◽  
Severe Toxicity ◽  
Genotype 3 ◽  
Count Nadir ◽  
Udp Glucuronosyltransferase

Purpose Severe toxicity is commonly observed in cancer patients receiving irinotecan. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the glucuronidation of the active metabolite SN-38. This study prospectively evaluated the association between the prevalence of severe toxicity and UGT1A1 genetic variation. Patients and Methods Sixty-six cancer patients with advanced disease refractory to other treatments received irinotecan 350 mg/m2 every 3 weeks. Toxicity and pharmacokinetic data were measured during cycle 1. UGT1A1 variants (−3279G>T, −3156G>A, promoter TA indel, 211G>A, 686C>A) were genotyped. Results The prevalence of grade 4 neutropenia was 9.5%. Grade 4 neutropenia was much more common in patients with the TA indel 7/7 genotype (3 of 6 patients; 50%) compared with 6/7 (3 of 24 patients; 12.5%) and 6/6 (0 of 29 patients; 0%) (P = .001). The TA indel genotype was significantly associated with the absolute neutrophil count nadir (7/7 < 6/7 < 6/6, P = .02). The relative risk of grade 4 neutropenia was 9.3 (95% CI, 2.4 to 36.4) for the 7/7 patients versus the rest of the patients. Pretreatment total bilirubin levels (mean ± standard deviation) were significantly higher in patients with grade 4 neutropenia (0.83 ± 0.08 mg/dL) compared to those without grade 4 neutropenia (0.47 ± 0.03 mg/dL; P < .001). The −3156G>A variant seemed to distinguish different phenotypes of total bilirubin within the TA indel genotypes. The −3156 genotype and the SN-38 area under the concentration versus time curve were significant predictors of ln(absolute neutrophil count nadir; r2 = 0.51). Conclusion UGT1A1 genotype and total bilirubin levels are strongly associated with severe neutropenia, and could be used to identify cancer patients predisposed to the severe toxicity of irinotecan. The hypothesis that the −3156G>A variant is a better predictor of UGT1A1 status than the previously reported TA indel requires further testing.

ANALISIS ABSOLUTE NEUTROPHIL COUNT DI PASIEN KANKER PAYUDARA DENGAN KEMOTERAPI

2016 ◽  
Vol 21 (3) ◽  
pp. 215
Author(s):  
Arifa Moidady ◽  
Tenri Esa ◽  
Uleng Bahrun
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Relative Number ◽  
Common Symptom ◽  
Breast Cancer Patients ◽  
Patient Age ◽  
Patient Âgé ◽  
The Absolute

The Absolute Neutrophil Count (ANC) is the absolute number of neutrophil derived from the multiplication of the relative number of leukocytes to the total neutrophil count. Neutrophils can be disturbed due to myelosupressive effects of chemotherapy. Fever is a common symptom in neutropenia patients due to chemotherapy. This fever is an emergency requiring rapid handling of Oncology and needs administration of appropriate antibiotics. Therefore, the data on the occurence of neutropenia and its related fever in patients whom accept chemotherapy after breast cancer it is important to be noted. This study is carried on to know the Absolute Neutrophil Count (ANC) in breast cancer patients with chemotherapy by analyzing them. The study was performed retrospectively by taking medical record data from January up to December 2012 in Dr. Wahidin Sudirohusodo Hospital Makassar. The absolute Neutrophil Count pre and afterchemotherapy analysis was done to determine neutropenia, as well as the febrile neutropenia and the correlation between ANC with patients age and stage of breast cancer. A total of 55 samples with the majority of patients (85.45%) were in the age group of 41–60 years old. The ANC after chemotherapy occurred in 50 patients were decreased (90.91%). There are five (5) patients (9.09%) with fever and two (2) persons (patients) (3.63%) suffered febrile neutropenia. The correlation analysis between decreased ANC with patient age and stage of breast cancer are p=0.054 and 0.070 respectively. Based on this study it can be concluded, that decreased ANC occurredin most patients after accepting chemotherapy but only few patients suffered febrile neutropenia. There was no significant correlation between the decreased ANC with patient age and stage of breast cancer

Sign in / Sign up

Export Citation Format

Share Document